| pubmed-article:15197803 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0039871 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:15197803 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:15197803 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:15197803 | pubmed:dateCreated | 2004-6-15 | lld:pubmed |
| pubmed-article:15197803 | pubmed:abstractText | High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as part of the initial treatment regimen improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma. The optimal preparative regimen for patients with multiple myeloma has yet to be defined. In the current study, the authors compared the outcomes associated with high-dose melphalan (HDM) and a more intensive regimen of thiotepa, busulfan, and cyclophosphamide (TBC) in patients with multiple myeloma. | lld:pubmed |
| pubmed-article:15197803 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15197803 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15197803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15197803 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15197803 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15197803 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:GiraltSergioS | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:Anagnostopoul... | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:ChamplinRicha... | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:WeberDonnaD | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:AlexanianRaym... | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:DonatoMichele... | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:AlemanAnaA | lld:pubmed |
| pubmed-article:15197803 | pubmed:author | pubmed-author:AyersGregoryG | lld:pubmed |
| pubmed-article:15197803 | pubmed:copyrightInfo | Copyright 2004 American Cancer Society. | lld:pubmed |
| pubmed-article:15197803 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15197803 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15197803 | pubmed:volume | 100 | lld:pubmed |
| pubmed-article:15197803 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15197803 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15197803 | pubmed:pagination | 2607-12 | lld:pubmed |
| pubmed-article:15197803 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:meshHeading | pubmed-meshheading:15197803... | lld:pubmed |
| pubmed-article:15197803 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15197803 | pubmed:articleTitle | Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. | lld:pubmed |
| pubmed-article:15197803 | pubmed:affiliation | Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. | lld:pubmed |
| pubmed-article:15197803 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15197803 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15197803 | lld:pubmed |
